Skip to main content

Articles

152 result(s) for 'mayo clinic' within Molecular Neurodegeneration

Page 1 of 4

  1. Plasma biomarkers reflecting the pathology of frontotemporal dementia would add significant value to clinical practice, to the design and implementation of treatment trials as well as our understanding of dise...

    Authors: Abbe Ullgren, Linn Öijerstedt, Jennie Olofsson, Sofia Bergström, Julia Remnestål, John C. van Swieten, Lize C. Jiskoot, Harro Seelaar, Barbara Borroni, Raquel Sanchez-Valle, Fermin Moreno, Robert Laforce, Matthis Synofzik, Daniela Galimberti, James B. Rowe, Mario Masellis…
    Citation: Molecular Neurodegeneration 2023 18:85
  2. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the loss of both upper and lower motor neurons, resulting in muscle weakness, atrophy, paralysis, and eventually...

    Authors: Manling Xie, Praveen N. Pallegar, Sebastian Parusel, Aivi T. Nguyen and Long-Jun Wu
    Citation: Molecular Neurodegeneration 2023 18:75
  3. Inclusions of TAR DNA-binding protein 43 kDa (TDP-43) has been designated limbic-predominant, age-related TDP-43 encephalopathy (LATE), with or without co-occurrence of Alzheimer’s disease (AD). Approximately,...

    Authors: Virginia Estades Ayuso, Sarah Pickles, Tiffany Todd, Mei Yue, Karen Jansen-West, Yuping Song, Jesús González Bejarano, Bailey Rawlinson, Michael DeTure, Neill R. Graff-Radford, Bradley F. Boeve, David S. Knopman, Ronald C. Petersen, Dennis W. Dickson, Keith A. Josephs, Leonard Petrucelli…
    Citation: Molecular Neurodegeneration 2023 18:57
  4. Mutations in the vacuolar protein sorting 35 ortholog (VPS35) gene cause late-onset, autosomal dominant Parkinson’s disease (PD), with a single missense mutation (Asp620Asn, D620N) known to segregate with disease...

    Authors: Xi Chen, Elpida Tsika, Nathan Levine and Darren J. Moore
    Citation: Molecular Neurodegeneration 2023 18:51
  5. Vascular cognitive impairment and dementia (VCID) is commonly caused by vascular injuries in cerebral large and small vessels and is a key driver of age-related cognitive decline. Severe VCID includes post-str...

    Authors: Yasuteru Inoue, Francis Shue, Guojun Bu and Takahisa Kanekiyo
    Citation: Molecular Neurodegeneration 2023 18:46
  6. More than 75 common variant loci account for only a portion of the heritability for Alzheimer’s disease (AD). A more complete understanding of the genetic basis of AD can be deduced by exploring associations w...

    Authors: Moonil Kang, Ting Fang Alvin Ang, Sherral A. Devine, Richard Sherva, Shubhabrata Mukherjee, Emily H. Trittschuh, Laura E. Gibbons, Phoebe Scollard, Michael Lee, Seo-Eun Choi, Brandon Klinedinst, Connie Nakano, Logan C. Dumitrescu, Alaina Durant, Timothy J. Hohman, Michael L. Cuccaro…
    Citation: Molecular Neurodegeneration 2023 18:40
  7. Alzheimer’s disease (AD) is a progressive and age-associated neurodegenerative disorder that affects women disproportionally. However, the underlying mechanisms are poorly characterized. Moreover, while the in...

    Authors: Lei Guo, Jiqing Cao, Jianwei Hou, Yonghe Li, Min Huang, Li Zhu, Larry Zhang, Yeji Lee, Mariana Lemos Duarte, Xianxiao Zhou, Minghui Wang, Chia-Chen Liu, Yuka Martens, Michael Chao, Alison Goate, Guojun Bu…
    Citation: Molecular Neurodegeneration 2023 18:39
  8. Peripheral inflammation, defined as inflammation that occurs outside the central nervous system, is an age-related phenomenon that has been identified as a risk factor for Alzheimer’s disease. While the role o...

    Authors: Keenan A. Walker, Lydia M. Le Page, Niccolò Terrando, Michael R. Duggan, Michael T. Heneka and Brianne M. Bettcher
    Citation: Molecular Neurodegeneration 2023 18:37
  9. Authors: Wenhui Qiao, Yixing Chen, Jun Zhong, Benjamin J. Madden, Cristine M. Charlesworth, Yuka A. Martens, Chia-Chen Liu, Joshua Knight, Tadafumi C. Ikezu, Aishe Kurti, Yiyang Zhu, Axel Meneses, Cassandra L. Rosenberg, Lindsey A. Kuchenbecker, Lucy K. Vanmaele, Fuyao Li…
    Citation: Molecular Neurodegeneration 2023 18:28

    The original article was published in Molecular Neurodegeneration 2023 18:8

  10. Mouse models that overexpress human mutant Tau (P301S and P301L) are commonly used in preclinical studies of Alzheimer’s Disease (AD) and while several drugs showed therapeutic effects in these mice, they were...

    Authors: Kathrin Wenger, Arthur Viode, Christoph N. Schlaffner, Patrick van Zalm, Long Cheng, Tammy Dellovade, Xavier Langlois, Anthony Bannon, Rui Chang, Theresa R. Connors, Derek Oakley, Bernhard Renard, Juri Rappsilber, Bradley Hyman, Hanno Steen and Judith A. Steen
    Citation: Molecular Neurodegeneration 2023 18:10
  11. The rare p.H157Y variant of TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) was found to increase Alzheimer’s disease (AD) risk. This mutation is located at the cleavage site of TREM2 extracellular domai...

    Authors: Wenhui Qiao, Yixing Chen, Jun Zhong, Benjamin J. Madden, Cristine M. Charlesworth, Yuka A. Martens, Chia-Chen Liu, Joshua Knight, Tadafumi C. Ikezu, Aishe Kurti, Yiyang Zhu, Axel Meneses, Cassandra L. Rosenberg, Lindsey A. Kuchenbecker, Lucy K. Vanmaele, Fuyao Li…
    Citation: Molecular Neurodegeneration 2023 18:8

    The Correction to this article has been published in Molecular Neurodegeneration 2023 18:28

  12. Alzheimer’s disease (AD) is neuropathologically characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The main protein components of these hallmarks include Aβ40, Aβ42, tau, phosphor-tau, and...

    Authors: Stephanie R. Oatman, Joseph S. Reddy, Zachary Quicksall, Minerva M. Carrasquillo, Xue Wang, Chia-Chen Liu, Yu Yamazaki, Thuy T. Nguyen, Kimberly Malphrus, Michael Heckman, Kristi Biswas, Kwangsik Nho, Matthew Baker, Yuka A. Martens, Na Zhao, Jun Pyo Kim…
    Citation: Molecular Neurodegeneration 2023 18:2
  13. We analyzed 35 population-based Mayo Clinic Study of Aging participants with plasma p-...

    Authors: Melissa E. Murray, Christina M. Moloney, Naomi Kouri, Jeremy A. Syrjanen, Billie J. Matchett, Darren M. Rothberg, Jessica F. Tranovich, Tiffany N. Hicks Sirmans, Heather J. Wiste, Baayla D. C. Boon, Aivi T. Nguyen, R. Ross Reichard, Dennis W. Dickson, Val J. Lowe, Jeffrey L. Dage, Ronald C. Petersen…
    Citation: Molecular Neurodegeneration 2022 17:85
  14. Cytoplasmic mislocalization and aggregation of TAR DNA-binding protein-43 (TDP-43) is a hallmark of the amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD) disease spectrum, causing both nuclea...

    Authors: Bilal Khalil, Deepak Chhangani, Melissa C. Wren, Courtney L. Smith, Jannifer H. Lee, Xingli Li, Christian Puttinger, Chih-Wei Tsai, Gael Fortin, Dmytro Morderer, Junli Gao, Feilin Liu, Chun Kim Lim, Jingjiao Chen, Ching-Chieh Chou, Cara L. Croft…
    Citation: Molecular Neurodegeneration 2022 17:80
  15. Abnormal lipid accumulation has been recognized as a key element of immune dysregulation in microglia whose dysfunction contributes to neurodegenerative diseases. Microglia play essential roles in the clearanc...

    Authors: Na Wang, Minghui Wang, Suren Jeevaratnam, Cassandra Rosenberg, Tadafumi C. Ikezu, Francis Shue, Sydney V. Doss, Alla Alnobani, Yuka A. Martens, Melissa Wren, Yan W. Asmann, Bin Zhang, Guojun Bu and Chia-Chen Liu
    Citation: Molecular Neurodegeneration 2022 17:75
  16. Alzheimer’s disease (AD) is the most common cause of dementia worldwide, and its prevalence is rapidly increasing due to extended lifespans. Among the increasing number of genetic risk factors identified, the ...

    Authors: Ana-Caroline Raulin, Sydney V. Doss, Zachary A. Trottier, Tadafumi C. Ikezu, Guojun Bu and Chia-Chen Liu
    Citation: Molecular Neurodegeneration 2022 17:72
  17. The aggregation and spread of α-synuclein (α-Syn) protein and related neuronal toxicity are the key pathological features of Parkinson’s disease (PD) and Lewy body dementia (LBD). Studies have shown that patho...

    Authors: Kai Chen, Yuka A. Martens, Axel Meneses, Daniel H. Ryu, Wenyan Lu, Ana Caroline Raulin, Fuyao Li, Jing Zhao, Yixing Chen, Yunjung Jin, Cynthia Linares, Marshall Goodwin, Yonghe Li, Chia-Chen Liu, Takahisa Kanekiyo, David M. Holtzman…
    Citation: Molecular Neurodegeneration 2022 17:57
  18. Microglia, the resident immune cells of the brain, play a critical role in numerous diseases, but are a minority cell type and difficult to genetically manipulate in vivo with viral vectors and other approache...

    Authors: Mika P. Cadiz, Tanner D. Jensen, Jonathon P. Sens, Kuixi Zhu, Won-Min Song, Bin Zhang, Mark Ebbert, Rui Chang and John D. Fryer
    Citation: Molecular Neurodegeneration 2022 17:26
  19. Across neurodegenerative diseases, common mechanisms may reveal novel therapeutic targets based on neuronal protection, repair, or regeneration, independent of etiology or site of disease pathology. To address...

    Authors: Lauren K. Wareham, Shane A. Liddelow, Sally Temple, Larry I. Benowitz, Adriana Di Polo, Cheryl Wellington, Jeffrey L. Goldberg, Zhigang He, Xin Duan, Guojun Bu, Albert A. Davis, Karthik Shekhar, Anna La Torre, David C. Chan, M. Valeria Canto-Soler, John G. Flanagan…
    Citation: Molecular Neurodegeneration 2022 17:23
  20. Epidemiological studies suggest a link between the melanoma-related pigmentation gene melanocortin 1 receptor (MC1R) and risk of Parkinson’s disease (PD). We previously showed that MC1R signaling can facilitate n...

    Authors: Waijiao Cai, Pranay Srivastava, Danielle Feng, Yue Lin, Charles R. Vanderburg, Yuehang Xu, Pamela Mclean, Matthew P. Frosch, David E. Fisher, Michael A. Schwarzschild and Xiqun Chen
    Citation: Molecular Neurodegeneration 2022 17:16
  21. Transactive response DNA binding protein of 43 kDa (TDP-43) is an intranuclear protein encoded by the TARDBP gene that is involved in RNA splicing, trafficking, stabilization, and thus, the regulation of gene exp...

    Authors: Axel Meneses, Shunsuke Koga, Justin O’Leary, Dennis W. Dickson, Guojun Bu and Na Zhao
    Citation: Molecular Neurodegeneration 2021 16:84
  22. Synucleinopathies are clinically and pathologically heterogeneous disorders characterized by pathologic aggregates of α-synuclein in neurons and glia, in the form of Lewy bodies, Lewy neurites, neuronal cytopl...

    Authors: Shunsuke Koga, Hiroaki Sekiya, Naveen Kondru, Owen A. Ross and Dennis W. Dickson
    Citation: Molecular Neurodegeneration 2021 16:83
  23. A detailed understanding of the pathological processes involved in genetic frontotemporal dementia is critical in order to provide the patients with an optimal future treatment. Protein levels in CSF have the ...

    Authors: Sofia Bergström, Linn Öijerstedt, Julia Remnestål, Jennie Olofsson, Abbe Ullgren, Harro Seelaar, John C. van Swieten, Matthis Synofzik, Raquel Sanchez-Valle, Fermin Moreno, Elizabeth Finger, Mario Masellis, Carmela Tartaglia, Rik Vandenberghe, Robert Laforce, Daniela Galimberti…
    Citation: Molecular Neurodegeneration 2021 16:79
  24. Parkinson’s disease is a disabling neurodegenerative movement disorder characterized by dopaminergic neuron loss induced by α-synuclein oligomers. There is an urgent need for disease-modifying therapies for Pa...

    Authors: Kevin S. Chen, Krystal Menezes, Jarlath B. Rodgers, Darren M. O’Hara, Nhat Tran, Kazuko Fujisawa, Seiya Ishikura, Shahin Khodaei, Hien Chau, Anna Cranston, Minesh Kapadia, Grishma Pawar, Susan Ping, Aldis Krizus, Alix Lacoste, Scott Spangler…
    Citation: Molecular Neurodegeneration 2021 16:77
  25. Mitochondrial dysfunction is a feature of neurodegenerative diseases, including Alzheimer’s disease (AD). Changes in the mitochondrial DNA copy number (mtDNAcn) and increased mitochondrial DNA mutation burden ...

    Authors: Hans-Ulrich Klein, Caroline Trumpff, Hyun-Sik Yang, Annie J. Lee, Martin Picard, David A. Bennett and Philip L. De Jager
    Citation: Molecular Neurodegeneration 2021 16:75
  26. Microtubule-associated protein tau is abnormally aggregated in neuronal and glial cells in a range of neurodegenerative diseases that are collectively referred to as tauopathies. Multiple studies have suggeste...

    Authors: Dah-eun Chloe Chung, Shanu Roemer, Leonard Petrucelli and Dennis W. Dickson
    Citation: Molecular Neurodegeneration 2021 16:57
  27. Human tauopathies including Alzheimer’s disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, which parallel the formation of insoluble Tau aggregates, neur...

    Authors: Maria Bichmann, Nuria Prat Oriol, Ebru Ercan-Herbst, David C. Schöndorf, Borja Gomez Ramos, Vera Schwärzler, Marie Neu, Annabelle Schlüter, Xue Wang, Liang Jin, Chenqi Hu, Yu Tian, Janina S. Ried, Per Haberkant, Laura Gasparini and Dagmar E. Ehrnhoefer
    Citation: Molecular Neurodegeneration 2021 16:46
  28. Passive immunotherapies targeting Aβ continue to be evaluated as Alzheimer’s disease (AD) therapeutics, but there remains debate over the mechanisms by which these immunotherapies work. Besides the amount of p...

    Authors: Yona Levites, Cory Funk, Xue Wang, Paramita Chakrabarty, Karen N. McFarland, Baxter Bramblett, Veronica O’Neal, Xufei Liu, Thomas Ladd, Max Robinson, Mariet Allen, Minerva M. Carrasquillo, Dennis Dickson, Pedro Cruz, Danny Ryu, Hong-Dong Li…
    Citation: Molecular Neurodegeneration 2021 16:32
  29. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Kevin Clayton, Jean Christophe Delpech, Shawn Herron, Naotoshi Iwahara, Maria Ericsson, Takashi Saito, Takaomi C. Saido, Seiko Ikezu and Tsuneya Ikezu
    Citation: Molecular Neurodegeneration 2021 16:24

    The original article was published in Molecular Neurodegeneration 2021 16:18

  30. Recent studies suggest that microglia contribute to tau pathology progression in Alzheimer’s disease. Amyloid plaque accumulation transforms microglia, the primary innate immune cells in the brain, into neurod...

    Authors: Kevin Clayton, Jean Christophe Delpech, Shawn Herron, Naotoshi Iwahara, Maria Ericsson, Takashi Saito, Takaomi C. Saido, Seiko Ikezu and Tsuneya Ikezu
    Citation: Molecular Neurodegeneration 2021 16:18

    The Correction to this article has been published in Molecular Neurodegeneration 2021 16:24

  31. The most common mutation in the Leucine-rich repeat kinase 2 gene (LRRK2), G2019S, causes familial Parkinson’s Disease (PD) and renders the encoded protein kinase hyperactive. While targeting LRRK2 activity is...

    Authors: Jillian H. Kluss, Melissa Conti Mazza, Yan Li, Claudia Manzoni, Patrick A. Lewis, Mark R. Cookson and Adamantios Mamais
    Citation: Molecular Neurodegeneration 2021 16:17
  32. Genome-wide association studies have established clusterin (CLU) as a genetic modifier for late-onset Alzheimer’s disease (AD). Both protective and risk alleles have been identified which may be associated wit...

    Authors: Fading Chen, Dan B. Swartzlander, Anamitra Ghosh, John D. Fryer, Baiping Wang and Hui Zheng
    Citation: Molecular Neurodegeneration 2021 16:5
  33. Accumulation of amyloid-β (Aβ) peptide in the brain is a pathological hallmark of Alzheimer’s disease (AD). The clusterin (CLU) gene confers a risk for AD and CLU is highly upregulated in AD patients, with the co...

    Authors: Aleksandra M. Wojtas, Jonathon P. Sens, Silvia S. Kang, Kelsey E. Baker, Taylor J. Berry, Aishe Kurti, Lillian Daughrity, Karen R. Jansen-West, Dennis W. Dickson, Leonard Petrucelli, Guojun Bu, Chia-Chen Liu and John D. Fryer
    Citation: Molecular Neurodegeneration 2020 15:71
  34. Late-onset Alzheimer’s disease (LOAD) is the most common form of dementia worldwide. To date, animal models of Alzheimer’s have focused on rare familial mutations, due to a lack of frank neuropathology from mo...

    Authors: Christoph Preuss, Ravi Pandey, Erin Piazza, Alexander Fine, Asli Uyar, Thanneer Perumal, Dylan Garceau, Kevin P. Kotredes, Harriet Williams, Lara M. Mangravite, Bruce T. Lamb, Adrian L. Oblak, Gareth R. Howell, Michael Sasner, Benjamin A. Logsdon and Gregory W. Carter
    Citation: Molecular Neurodegeneration 2020 15:67
  35. Investigations of apolipoprotein E (APOE) gene, the major genetic risk modifier for Alzheimer’s disease (AD), have yielded significant insights into the pathogenic mechanism. Among the three common coding variant...

    Authors: Zonghua Li, Francis Shue, Na Zhao, Mitsuru Shinohara and Guojun Bu
    Citation: Molecular Neurodegeneration 2020 15:63
  36. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Xue Wang, Mariet Allen, Shaoyu Li, Zachary S. Quicksall, Tulsi A. Patel, Troy P. Carnwath, Joseph S. Reddy, Minerva M. Carrasquillo, Sarah J. Lincoln, Thuy T. Nguyen, Kimberly G. Malphrus, Dennis W. Dickson, Julia E. Crook, Yan W. Asmann and Nilüfer Ertekin-Taner
    Citation: Molecular Neurodegeneration 2020 15:54

    The original article was published in Molecular Neurodegeneration 2020 15:38

  37. Large-scale brain bulk-RNAseq studies identified molecular pathways implicated in Alzheimer’s disease (AD), however these findings can be confounded by cellular composition changes in bulk-tissue. To identify ...

    Authors: Xue Wang, Mariet Allen, Shaoyu Li, Zachary S. Quicksall, Tulsi A. Patel, Troy P. Carnwath, Joseph S. Reddy, Minerva M. Carrasquillo, Sarah J. Lincoln, Thuy T. Nguyen, Kimberly G. Malphrus, Dennis W. Dickson, Julia E. Crook, Yan W. Asmann and Nilüfer Ertekin-Taner
    Citation: Molecular Neurodegeneration 2020 15:38

    The Correction to this article has been published in Molecular Neurodegeneration 2020 15:54

  38. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Xiaoqiang Tang, Arturo Toro, T. G. Sahana, Junli Gao, Jessica Chalk, Björn Oskarsson and Ke Zhang
    Citation: Molecular Neurodegeneration 2020 15:37

    The original article was published in Molecular Neurodegeneration 2020 15:34

  39. Ever since a GGGGCC hexanucleotide repeat expansion mutation in C9ORF72 was identified as the most common cause of familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), three competing b...

    Authors: Xiaoqiang Tang, Arturo Toro, Sahana T.G., Junli Gao, Jessica Chalk, Björn E. Oskarsson and Ke Zhang
    Citation: Molecular Neurodegeneration 2020 15:34

    The Correction to this article has been published in Molecular Neurodegeneration 2020 15:37

  40. Frontotemporal lobar degeneration (FTLD) is a devastating and progressive disorder, and a common cause of early onset dementia. Progranulin (PGRN) haploinsufficiency due to autosomal dominant mutations in the ...

    Authors: Jonathan Frew, Alireza Baradaran-Heravi, Aruna D. Balgi, Xiujuan Wu, Tyler D. Yan, Steve Arns, Fahimeh S. Shidmoossavee, Jason Tan, James B. Jaquith, Karen R. Jansen-West, Francis C. Lynn, Fen-Biao Gao, Leonard Petrucelli, Howard H. Feldman, Ian R. Mackenzie, Michel Roberge…
    Citation: Molecular Neurodegeneration 2020 15:21
  41. The C9ORF72 hexanucleotide repeat expansion is the most common known genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two fatal age-related neurodegenerative diseases. Th...

    Authors: Nadja S. Andrade, Melina Ramic, Rustam Esanov, Wenjun Liu, Mathew J. Rybin, Gabriel Gaidosh, Abbas Abdallah, Samuel Del’Olio, Tyler C. Huff, Nancy T. Chee, Sadhana Anatha, Tania F. Gendron, Claes Wahlestedt, Yanbin Zhang, Michael Benatar, Christian Mueller…
    Citation: Molecular Neurodegeneration 2020 15:13